Sort by
Refine Your Search
-
, develop business cases and more. At the 6-month point, students progress onto their interdisciplinary PhD research project, supervised jointly by two academics from two research groups. Usually, supervisors
-
for complex data accessible to the scientific community and to produce innovative methodology related to trial designs, longitudinal and event history data, precision medicine, causal inference, AI/machine
-
non-clinical PhD studentship in cardiometabolic research, commencing October 2026 in the Department of Medicine (VPD Heart & Lung Research Institute), University of Cambridge. The project will be based
-
Location: West Cambridge The world-renowned Cavendish Laboratory is seeking an enthusiastic, self-motivated student who enjoys working as part of a team to undertake a PhD in the NanoPhotonics Group
-
We invite applications from creative and motivated individuals to join Professor Sir Shankar Balasubramanian's group for a 4-year PhD studentship, working on a multidisciplinary project exploiting
-
PhD studentship: Defining the role of the pioneer factor FOXA1 in hormone-dependent cancer Supervisor: Professor Jason Carroll Course start date: 1st October 2026 Project details For further
-
This is a four-year (1+3 MRes/PhD) studentship funded through the Cambridge EPSRC Centre for Doctoral Training in Future Infrastructure and Built Environment: Unlocking Net Zero (FIBE3 CDT). Further
-
also throughout the development phase, which involves transforming a molecule into a medicine and addressing various chemistry, manufacturing, and control (CMC) challenges. A key aspect of this process
-
conserved mechanism to suppress endogenous retroviruses across the Drosophila genus. Nature Communications. Alizada A, et al. (2024). Transcriptional regulation of the piRNA pathway by Ovo in animal ovarian
-
of the chromatin landscape in prostate cancer. Nat Commun. 2022 Apr 27;13(1):2282 https://pubmed.ncbi.nlm.nih.gov/35477723/ Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer